New hope for tough lymphoma: experimental drug shows promise in shrinking tumors
NCT ID NCT05563844
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 32 times
Summary
This study tests a new drug called purinostat mesylate in about 74 adults with diffuse large B-cell lymphoma that has returned or not improved after prior therapy. The goal is to see if the drug can shrink tumors and control the cancer safely. Participants receive the drug by injection, and researchers monitor tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital of Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.